Showing results (11-20 of 159) with videos related to
Sort By:
Pageof 16
Leukemia & Lymphoma|March 11, 2017
Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progressionMelanie T Rebechi, Keith W PratzJournal of Hematology & Oncology|March 25, 2023
Recent advances in targeted therapies in acute myeloid leukemiaRahul S Bhansali, Keith W Pratz, Catherine LaiCancers|December 11, 2022
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid LeukemiaAndrew H Matthews, Keith W Pratz, Martin P CarrollBlood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.Current Opinion in Hematology|December 18, 2004
Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemiaMark LevisHematology. American Society of Hematology. Education Program|December 10, 2013
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Mark LevisMedicine|July 17, 2007
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemiaKeith W Pratz, David Dingli, Thomas C Smyrk, et al.Pageof 16